Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M52,323Revenue $M2,820Net Margin (%)11.7Altman Z-Score28.0
Enterprise Value $M52,054EPS $3.1Operating Margin %30.6Piotroski F-Score4
P/E(ttm)161Beneish M-Score-2.5Pre-tax Margin (%)28.6Higher ROA y-yN
Price/Book17.510-y EBITDA Growth Rate %--Quick Ratio4.1Cash flow > EarningsY
Price/Sales19.05-y EBITDA Growth Rate %--Current Ratio4.3Lower Leverage y-yY
Price/Free Cash Flow262y-y EBITDA Growth Rate %9.3ROA % (ttm)9.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)14.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M103ROIC % (ttm)17.5Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNKen Fisher 2015-03-31 Add$396.89 - $488.87
($423.8)
$ 506.4520%Add 1.91%534
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 506.4529%Add 4.49%2,921,000
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 506.4529%Sold Out0
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 506.4551%Add 60.05%1,410
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 506.4551%New holding583
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 506.4571%Add 60.34%2,795,500
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 506.4571%New holding881
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 506.4571%New holding2,295
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 506.4565%Add 23.47%1,743,468
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 506.4565%New holding6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 506.4576%Sold Out0
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 506.4593%New holding3,285
REGNVanguard Health Care Fund 2013-03-31 Add0.62%$158.42 - $183.77
($171.66)
$ 506.45195%Add 170.41%1,412,100
REGNVanguard Health Care Fund 2012-09-30 Reduce-0.09%$112.77 - $152.66
($135.2)
$ 506.45275%Reduce 24.56%522,200
REGNDodge & Cox 2012-03-31 Sold Out $57.83 - $119.96
($92.23)
$ 506.45449%Sold Out0
REGNCarl Icahn 2011-09-30 Sold Out -1.76%$44.96 - $72.19
($58.66)
$ 506.45763%Sold Out0
REGNDodge & Cox 2011-09-30 Reduce-0.03%$44.96 - $72.19
($58.66)
$ 506.45763%Reduce 97.62%9,400
REGNVanguard Health Care Fund 2011-09-30 Add0.03%$44.96 - $72.19
($58.22)
$ 506.45770%Add 15.37%692,200
REGNDodge & Cox 2011-03-31 Buy 0.02%$32.61 - $44.68
($36.41)
$ 506.451291%New holding375,685
REGNVanguard Health Care Fund 2011-03-31 Reduce$32.61 - $44.94
($36.59)
$ 506.451284%Reduce 3.21%600,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BROWN MICHAEL SDirector 2015-05-15Sell5,000$4953.81view
BAKER CHARLES ADirector 2015-03-25Sell5,000$454.9612.95view
Aberman Michael SSVP Strategy Investor Relation 2015-03-24Sell4,843$478.997.28view
Aberman Michael SSVP Strategy Investor Relation 2015-03-18Sell3,442$46510.51view
Terifay Robert JSVP Commercial 2015-03-17Sell10,993$451.0113.94view
LAROSA JOSEPH JSVP General Counsel and Secret 2015-03-16Sell18,311$45014.2view
McCorkle Douglas SVP Controller and Asst Treasur 2015-02-27Sell3,000$416.2423.46view
Tessier-Lavigne MarcDirector 2015-02-26Sell3,000$421.9521.79view
Aberman Michael SSVP Strategy Investor Relation 2015-02-24Sell3,374$418.4822.8view
Terifay Robert JSVP Commercial 2015-02-24Sell11,173$423.6721.29view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
    1 Feb 23 2015 
    1 Feb 23 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 

    More From Other Websites
    Fight over hot new cholesterol drugs may be won in milligrams May 26 2015
    The Most Loved Biotechs of Big Hedge Funds May 23 2015
    What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds May 23 2015
    3 Top IBD 50 Stocks Hit New All-Time Highs May 21 2015
    Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog May 21 2015
    Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
    Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
    Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
    Cramer: This is the absolute worst thing in this market May 20 2015
    Cramer: Bail out now on this group May 20 2015
    Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying May 20 2015
    Move Over Chip Stocks: Here Are 5 Top Biotechs May 20 2015
    10 S&P 500 Companies to Have the Most Revenue Growth in 2015 May 20 2015
    Cramer's Mad Dash: Regeneron goes higher May 20 2015
    Cramer: This went from $5 to $500 and isn't done May 19 2015
    Healthcare Winners and Losers: May 19, 2015 May 19 2015
    Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog May 19 2015
    Regeneron Shares Seen Reaching $525 May 19 2015
    Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015
    Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK